Stocktoria
Annexon, Inc. ANNX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-07-24
Annexon, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $184.7M | $119.4M | $113.8M | $112.5M | $100.1M |
| Operating income | -$216.4M | -$154.1M | -$143.7M | -$145.6M | -$130.7M |
| Income tax | $0 | $0 | $0 | $0 | — |
| Net income | -$206.7M | -$138.2M | -$134.2M | -$141.9M | -$130.3M |
| EPS (diluted) | $-1.34 | $-1.01 | $-1.77 | $-2.60 | $-3.40 |
| Operating cash flow | -$186.4M | -$118.0M | -$121.1M | -$116.3M | -$106.1M |
| Free cash flow | -$186.5M | -$118.0M | -$121.3M | -$122.8M | -$107.8M |
| Cash & equivalents | $162.1M | $49.5M | $225.1M | $140.0M | $74.8M |
| Total assets | $277.6M | $350.1M | $297.7M | $285.1M | $287.0M |
| Total liabilities | $65.9M | $57.0M | $47.1M | $53.9M | $55.1M |
| Shareholders' equity | $211.6M | $293.1M | $250.6M | $231.2M | $231.9M |
Source: SEC EDGAR filings · CIK 0001528115 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.